CD47 and Anaplastic (Malignant) Meningioma: Taken together, these results demonstrated the limitations on immunotherapy associated with PD-L1 which worked with T lymphocytes, and it also raised the possibility of CD47 as a potential therapeutic target for malignant meningioma, since macrophages are significantly enriched in malignant meningioma.